AIM ImmunoTech (AIM) Q3 2024 earnings summary

Executive summary

• Advanced Ampligen clinical and regulatory programs in pancreatic cancer, post-COVID fatigue, and ME/CFS, with positive trial data and published long-term results.

• Net loss for Q3 2024 was $3.7M, a 53% improvement year-over-year, driven by lower R&D and G&A expenses, higher investment gains, and increased other income.

• Revenue for Q3 2024 was $35K, down from $46K in Q3 2023, reflecting lower patient participation in the Ampligen Cost Recovery Program.

• Expanded Ampligen's IP portfolio with a new patent for endometriosis treatment.

• Company remains focused on R&D for Ampligen and Alferon N Injection, with no FDA approval for Ampligen in the US but commercial approval in Argentina for CFS.

Financial highlights

• Q3 2024 net loss: $3.7M vs. $7.8M in Q3 2023; nine-month net loss: $11.4M vs. $16.4M prior year.

• R&D expenses for Q3 2024: $1.4M (down $1.3M YoY); G&A expenses: $3.1M (down $2.4M YoY).

• Disputing and negotiating $4.9 million in accounts payable; seeking resolution.

• One D&O insurance company has not paid a $2.5 million secondary coverage layer; efforts ongoing to secure payment.

• Cash and equivalents plus marketable securities at September 30, 2024: $7.2M, down $5.9M from year-end 2023.

Outlook and guidance

• Management believes current funds are adequate for operational needs and clinical trials for about 15 months but highlights the need for additional funding for new or expanded studies.

• Durapanc study on track for final patient enrollment by year-end, with phase II launch anticipated in Q1 2025.

• AMP-270 protocol for pancreatic cancer maintenance therapy updated and IRB approved; site recruitment underway.

• Ovarian cancer trial downsized due to strong response; manuscript submission planned by year-end.

• Post-COVID fatigue trial data to be posted by end of November; next study design to target moderate to severe patients with specific biomarkers.